North Carolina Macular Dystrophy: Phenotypic Variability and Computational Analysis of Disease-Associated Noncoding Variants

Purpose North Carolina macular dystrophy (NCMD) is an autosomal dominant, congenital disorder affecting the central retina. Here, we report clinical and genetic findings in three families segregating NCMD and use epigenomic datasets from human tissues to gain insights into the effect of NCMD-implicated variants. Methods Clinical assessment and genetic testing were performed. Publicly available transcriptomic and epigenomic datasets were analyzed and the activity-by-contact method for scoring enhancer elements and linking them to target genes was used. Results A previously described, heterozygous, noncoding variant upstream of the PRDM13 gene was detected in all six affected study participants (chr6:100,040,987G>C [GRCh37/hg19]). Interfamilial and intrafamilial variability were observed; the visual acuity ranged from 0.0 to 1.6 LogMAR and fundoscopic findings ranged from visually insignificant, confluent, drusen-like macular deposits to coloboma-like macular lesions. Variable degrees of peripheral retinal spots (which were easily detected on widefield retinal imaging) were observed in all study subjects. Notably, a 6-year-old patient developed choroidal neovascularization and required treatment with intravitreal bevacizumab injections. Computational analysis of the five single nucleotide variants that have been implicated in NCMD revealed that these noncoding changes lie within two putative enhancer elements; these elements are predicted to interact with PRDM13 in the developing human retina. PRDM13 was found to be expressed in the fetal retina, with greatest expression in the amacrine precursor cell population. Conclusions We provide further evidence supporting the role of PRDM13 dysregulation in the pathogenesis of NCMD and highlight the usefulness of widefield retinal imaging in individuals suspected to have this condition.

chromosome 6 located approximately 13,000 base-pairs from the neighboring gene. At least five single nucleotide changes and three copy number variants in this region have been associated with NCMD. 1,3,4,9,15 These mutations alter DNA sequences that are likely to play a role in regulating the spatiotemporal expression of a retinal transcription factor PRDM13. PRDM13 is expressed in the fetal retina, but is not found in adult tissues. 1 Overexpression of this gene has been shown to affect retinal development in nonprimate animal models. 16 Intriguingly, changes near PRDM13 that have been associated with NCMD have also been implicated in a different condition, progressive bifocal chorioretinal atrophy (PBCRA). Although both of these disorders affect the macula from birth, the latter is typically associated with disease progression and electrophysiologic evidence of widespread retinal dysfunction. 2 It is also noteworthy that a number of individuals with a phenotype indistinguishable from NCMD have been found to have copy number variants in a different locus in chromosome 5. 1,2 NCMD is part of an expanding group of Mendelian conditions caused by noncoding genetic variants that have an effect on gene expression (e.g., aniridia, 17 limb malformations 18 ). These variants often alter the sequence of regulatory elements, including transcriptional promoters and enhancers. Enhancers are short stretches of DNA, typically a few hundred base-pairs long, that bind transcription factors and enhance the expression of specific genes. 19 There are hundreds of thousands of enhancers in the human genome but our understanding of their properties and repertoire is limited (e.g., where they reside, what genes they mediate their effects through, in which cells and in which specific time of development they act). Notably, our ability to detect and annotate enhancer elements is being transformed by emerging resources and tools such as the Encyclopedia of DNA Elements (ENCODE) 3 dataset, 20 the Developmental Single Cell Atlas of Gene Regulation and Expression (DESCARTES), 21,22 and the activity-by-contact (ABC) model. 23,24 The ENCODE project consortium and the DESCARTES team have generated extensive functional genomic datasets across many cell and tissue contexts. Experiments conducted include assays aiming to identify enhancer elements such as DNase-seq (DNase I hypersensitive site sequencing), H3K27ac ChIP-seq (chromatin immunoprecipitation sequencing mapping H3K27 acetylation signals), and ATAC-seq (assay for transposase-accessible chromatin using sequencing), as well as assays studying the 3-dimensional architecture of the genome such as Hi-C (all-versus-all chromosome conformation capture). [20][21][22] ABC, in contrast, is a method that uses these epigenomic data to predict which enhancers regulate which genes. This model is based on the notion that an enhancer's effect on a gene depends on the enhancer's strength (estimated using chromatin accessibility data including ATAC-seq and H3K27ac ChIP-seq data) weighted by how often it comes into three-dimensional contact with the gene promoter (estimated using Hi-C data). 23,24 Although this method has been shown to be accurate, a limiting factor is the availability of tissue-specific chromatin accessibility datasets. Comprehensive tissue-specific Hi-C data are also lacking, but the developers of ABC expect that Hi-C profiles averaged across a selection of cell types are adequate to map enhancer-gene connections. However, it remains possible that tissue-and context-specific data are required in some cases because the three-dimensional conformation of the genome shows some plasticity during development. 25 Although epigenomic datasets from various eye tissues are becoming increasingly available, 26 there have been no systematic efforts to characterize enhancers that contribute to human vision.
In this report, we discuss phenotypic variability in individuals who have NCMD and are heterozygous for a specific noncoding variant, chr6:100,040,987G>C (GRCh37/hg19). We then use the ABC method and human transcriptomic and epigenomic datasets to gain mechanistic insights into the role of noncoding variation in NCMD.

Participant Ascertainment, Phenotypic Data Collection, and Clinical Genetic Testing
Six individuals with a diagnosis of NCMD were retrospectively ascertained through the database of the North West Genomic Laboratory Hub, Manchester, UK. The study participants originated from three reportedly unrelated families who had European ancestries. The genetic and, to an extent, the clinical findings from two of the three affected individuals in one of these families have been reported previously. 15 Ethics committee approval for the study was obtained from the North West Research Ethics Committee (11/NW/0421 and 15/YH/0365) and all investigations were conducted in accordance to the tenets of the Declaration of Helsinki.
All study participants were diagnosed with NCMD through the tertiary ophthalmic genetics service at Manchester University NHS Foundation Trust, Manchester, UK. Clinical assessment included visual acuity testing, dilated fundus examination, digital widefield fundus imaging, fundus autofluorescence imaging, optical coherence tomography (OCT), and OCT-angiography (OCT-A). The Optos system (Optos PLC, Dunfermline, Scotland, UK) was used to obtain widefield images, the Topcon DRI OCT Triton device (Topcon GB, Newberry, Berkshire, UK) was used to obtain OCT and OCT-A scans, and the Spectralis system (Heidelberg Engineering, Heidelberg, Germany) was used to acquire fundus autofluorescence and OCT images in study participants.
Genetic testing was performed at the North West Genomic Laboratory Hub, a UK Accreditation Service (UKAS) Clinical Pathology Accredited (CPA) medical laboratory (CPA identifier, no. 4015). DNA samples from all study participants were screened using Sanger sequencing (BigDye v3.1) for the presence of known NCMDassociated variants in chromosome 6 (upstream of the PRDM13 gene 1 ). Two affected individuals also underwent genome sequencing as previously described (case 89794.1 27 and case 75898.2 15 ) ( Fig. 1 and Table 1); the generated data were used for haplotype analysis (Supplementary Table S1).

Analysis of Variants Associated With NCMD
To gain insights into the frequency of NCMD-associated variants in the general population, we queried the Genome Aggregation Database (gnomAD; version 3.1) and the NHLBI Trans-Omics for Precision Medicine variant database (TOPMed; freeze 8). Neither of these cohorts is known to be enriched for patients with ophthalmic conditions. 28,29 All variants known to be associated with NCMD (including the chr6:100,040,987G>C change detected in the study participants) were assessed using in silico tools that attempt to predict the deleteriousness of noncoding sequence FIGURE 1. Pedigrees from three families segregating NCMD. Study participants are highlighted with asterisks. We note that findings from the two affected females from family 75898 are also discussed in. 15 alterations. The following tools were used: CADD (Combined Annotation Dependent Depletion) v1.6, 30 nCER (NonCoding Essential Regulation) v2, 31 and regBase v1.1. 32 Position-specific evolutionary constraint was evaluated using GERP (Genomic Evolutionary Rate Profiling) scores 33 obtained through the University of California, Santa Cruz genome browser (available at: https://genome.ucsc.edu/).
To investigate the functional effects of the variants associated with NCMD, we queried the v109 release of the ENCODE portal for putative enhancer elements spanning the location of each variant; the SCREEN (Search Candidate cis-Regulatory Elements by ENCODE) v10 interface was used. 20 We also inspected the expression quantitative trait loci (eQTL) catalogue and the Genotype-Tissue Expression (GTEx) and Eye Genotype Expression (EyeGEx) datasets for eQTL overlapping any of the detected elements (in addition to elements predicted in our subsequent analyses). 34,35 We then queried the DESCARTES chromatin accessibility database for the location of NCMD-associated variants across all available tissues.
The ABC method for scoring enhancer elements and linking them to target genes was subsequently used. 23,24 Raw ATAC-seq and H3K27ac ChIP-seq reads from macular and retinal tissue were obtained from a publicly available dataset (GEO accession: GSE137311). 26 The data were then processed using a consistent pipeline. The raw reads were trimmed for quality and adaptor content using the fastp tool with default quality control options. 36 The trimmed ATACseq and ChIP-seq reads were aligned to the GRCh37/hg19 reference sequence using bowtie2 version 2.3.0 with the default parameters. 37 The alignments were inspected in picard tools version 2.1.0 (https://broadinstitute.github.io/ picard/) and duplicate reads were removed. Only reads with a mapping quality of 30 or higher were retained in subsequent analyses after filtration using the samtools "-view" command (version 1.9). 38 The ABC method was then used to produce a set of potential enhancers using default parameters. As described by Fulco et al., initial peaks were obtained using the MACS2 (Model-based Analysis of ChiP-Seq 2) peak caller on aligned ATAC-seq reads with a lenient P value using the following options "-g hs, -p .1, -call-summits." 39 The peaks were then extended by 250 base-pairs from their summits to produce a set of 500 base-pair candidate regions; overlapping regions were then merged. This process resulted in a broad set of potential regulatory elements whose activity could be scored. To accomplish this goal, the ATAC-seq and H3K27ac ChIP-seq reads overlapping each candidate region were counted and averaged over biological replicates using the ABC "call neighborhoods" script. Finally, Hi-C data from human embryonic stem cells were downloaded from the juicebox archive at 5000 base-pair resolution. 25 Averaged Hi-C data provided by the ABC GitHub page were also used; these data were produced by averaging the Hi-C profiles from 10 cell types (GM12878, NHEK, HMEC, RPE1, THP1, IMR90, HUVEC, HCT116, K562, and KBM7). ABC scores were calculated by combining the estimated contact frequency (between the candidate region and the promoter of a gene) with the observed activity using the default parameters.

Analysis of PRDM13 Gene Expression in the Human Retina
To determine the expression level of PRDM13, we used a resource collecting human RNA-seq datasets: eyeIntegration. 40 All retinal tissue subtypes, RPE subtypes, and progenitor subtypes were queried. Because eyeIntegration does not presently contain data on macula, PRDM13 expression was also estimated from three macula RNA-seq samples included in the GEO dataset GSE137311. 26 In short, the raw reads were quantified using salmon 41 (according to the same protocol used to build the eyeIntegration dataset) and the value in transcripts per million (TPM) was calculated using tximport to merge reads to the gene level with the "length-ScaledTPM" option. The source code for this pipeline can be found at: https://github.com/davemcg/scEiaD/. DESCARTES (available at: https://descartes.brotmanbaty.org/) was also queried for PRDM13 expression. Finally, PRDM13 expression was determined in individual cell types using the plae (PLatform for Analysis of scEiad version 0.43) database (available at: https://plae.nei.nih.gov/).

Clinical Characteristics of Study Participants
All six study participants were heterozygous for the chr6:100,040,987G>C variant. This change has been detected previously in a number of families segregating NCMD 1,3,4,15 and seemed to be on the same genetic background (haplotype) in at least two of the families included in this study (families 75898 and 89794) (Supplementary Table S1).
The age at presentation of study participants ranged from 3 to 46 years of age and the visual acuity ranged from 0.0 to 1.6 LogMAR. Three related patients presented in the first years of life and had vision of 0.5 LogMAR or worse; the remaining three patients had normal vision and were only found to have drusen-like macular lesions on routine eye tests. The clinical findings are discussed in Table 1, the pedigrees are shown in Figure 1, and fundus imaging results are shown in Figures 2 and 3. The central macular changes resembled fine, confluent drusen; these lesions were hyperautofluorescent on fundus autofluorescence imaging and only partially corresponded to visible OCT changes. A notable finding in all participants was that of characteristic yellow-white drusen-like retinal lesions in the far periphery; these lesions generally had a linear, radial configuration and could be detected on widefield imaging (Fig. 3). The youngest study participant developed choroidal neovascularization in both maculae (diagnosed at 6 years of age). An active lesion was noted in the right eye on OCT-A and treatment with intravitreal bevacizumab injections was initiated. However, persistent subretinal fluid was present after four injections.

In Silico Analysis of Variants Associated With NCMD
To date, five NCMD-associated single nucleotide variants have been reported in the biomedical literature. These variants were found to be extremely rare upon inspection of large-scale genomic datasets (gnomAD and TOPMed; Table  2). Notably, the chr6:100,040,987G>C change that was detected in the participants of this study was only identified in a single individual in gnomAD; this person was estimated to have European ancestry. None of the five NCMD-associated variants was predicted to be deleterious by CADD. According to nCER, the variants ranged from low to middle percentiles. 42 The regBase Phred-like scores ranged from 5.7 to 19.8 on a Phred-like scale from 1 to 99, with higher scores suggesting greater pathogenicity. Inspection of the UniPROBE (Universal PBM Resource for Oligonucleotide Binding Evaluation) database 42 revealed that none of these disease-associated variants is expected to significantly impact on a transcription factor binding site. The GERP scores ranged from -2.44 to 2.52, suggesting variable evolutionary constraint ( Table 2).
The degree to which NCMD-associated variants map to putative enhancer elements was then investigated. Two such elements were found in the ENCODE dataset to span the locations of all five disease-associated variants (accessions, EH37E1264999 and EH37E1265001l; DNase Z-scores, 3.81 and 1.70). We used the ABC method to assign these enhancers to target genes. Publicly available chromatin accessibility (ATAC-seq and H3K27ac ChIP-seq) datasets from macula and retina were used. 26 The Hi-C data recommended and provided by Fulco et al. 23 were also used; these consist of a Hi-C profile that was averaged over a number of cell types. With this input, ABC did not yield any predictions for the regions spanning the location of NCMD-associated variants. We then used the same ATAC-seq and H3K27ac ChIP-seq data, but this time combined with Hi-C data from human embryonic stem cells. In macula, two predicted enhancers encompassed the locations of all five variants, and these regions were linked to the FLH5, SIM1, and PRDM13 genes.
Because previous reports have associated PRDM13 with NCMD, 1,2,8 we then looked for enhancer elements predicted to be linked to PRDM13. Only elements that were within 100,000 base-pairs of the transcription initiation site were analyzed. This process yielded a total of 53 candidate regions in macular tissue and 47 candidate regions in retinal tissue. To determine which of these candidates have the strongest regulatory effects on PRDM13, putative enhancers were ranked according to the overall ABC score and to the individual components of this score (i.e., activity and contact) in isolation. The top 10 predicted elements ranked by their ABC scores are shown in Supplementary Tables S2  and S3.
One previously reported NCMD-associated variant, chr6:100,046,783A>C, fell within a predicted enhancer that spanned approximately the same coordinates in FIGURE 3. Digital widefield fundus imaging and fundus autofluorescence imaging in three probands who have NCMD and are heterozygous for the chr6:100,040,987 variant (GRCh37/hg19). Images from a 6-year-old (A), a 36-year-old (B), and a 48-year-old (C) are shown. Yellowwhite retinal spots, often very prominent and in radial alignment, are noted in the far temporal periphery of these three individuals. These spots correspond to hyperautofluorescent lesions on fundus autofluorescence imaging. White arrows are used to highlight some of these changes. Inferior lash artefact is noted in some images. There was a high degree of interocular symmetry and only data from the left eye are shown. It is worth noting that although there was significant phenotypic variability, widefield imaging revealed a maculopathy combined with peripheral drusen-like spots in all study participants. both macula and retina (chr6:100,046,330-100,046,830 and chr6;100,046,348-100,046,848, respectively) (Fig. 4). In terms of ranking, this enhancer had low scores for activity but relatively high scores for Hi-C contact when data from embryonic stem cells were used. Another four variants (chr6:100,040,906G>T, chr6:100,040,974A>C, chr6:100,040,987G>C, and chr6:100,041,040C>T) fell within a predicted enhancer spanning the chr6:100,040,653-100,041,153 region. This enhancer was found in macular tissue but not in retina, and had low scores for activity but relatively high scores for Hi-C contact.
Finally, we could not identify any significant singletissue eQTLs within any of the enhancer elements found in ENCODE or those predicted by the ABC method. Data from multiple tissues were inspected (including retinal samples from EyeGEx 35 ).

PRDM13 Gene Expression in the Developing and Adult Human Retina
To gain insights into the cellular context in which the PRDM13 gene product exerts its function, we evaluated the levels of gene expression in a number of relevant tissues (Fig. 5). The expression levels were significantly higher in the retina and macula than in the RPE, with the highest level found in fetal retinal tissue. Analysis of single-cell RNAseq datasets revealed that PRDM13 is expressed in progenitor cells (including amacrine/horizontal precursors), with higher expression in the amacrine population. PRDM13 had low expression levels (<0.2 TPM) in all tissues found in the GTEx project dataset. For further detail on the expression of PRDM13 across tissues and cell types, see Supplementary  Table S4 and Supplementary Figure S1. The CADD score ranges from 1 to 99; a higher score indicates greater pathogenicity. Values of 10 or greater are predicted to be the 10% most deleterious substitutions and values of 20 or greater in the 1% most deleterious.
The nCER scores are percentiles. The higher the percentile, the more likely that a region is vital in terms of regulation. There is no agreed cut-off for deleteriousness but the original report focused on assessing the predictive power of the higher percentiles (≥95th).
The regBase scores are Phred-like and calculated using the "PAT" model, which attempts to determine whether a variant is deleterious. The scores range from 1 to 99; a higher score indicates greater pathogenicity.
The GERP scores represent position-specific evolutionary constraint. Positive values suggest evolutionarily constrained positions, with a cut-off of 2 providing high sensitivity. * The relevant family described by Silva et al 2 includes a female proband with NCMD and her son who has been noted to have progressive bifocal chorioretinal atrophy (PBCRA). Although the son seems to have a more severe developmental maculopathy than his mother; the clinical information provided in the original report suggests that his phenotype is more in keeping with NCMD than with PBCRA. Notably, a nearby variant, chr6:100,046,804T>C (GRCh37/hg19), has been found to cause PBCRA in six affected individuals from two families (see also Fig. 4). 2 FIGURE 4. Location of enhancer elements upstream of PRDM13 in macula and retina as predicted by the ABC model. 23 A putative enhancer encompasses the chr6:100,040,987G>C (GRCh37/hg19) variant, which was carried by the six study participants (green line in the variant row). The enhancer encompassing this variant was not detected in retinal tissue and was only highlighted when a dataset from macular tissue was used. This enhancer overall encompasses four variants that were previously identified in families with NCMD: chr6:100,040,906G>T, chr6:100,040,974A>C, chr6:100,040,987G>C, and chr6:100,041,040C>T. A different candidate enhancer that was predicted to be functional in both macular and retinal tissue was altered by the chr6:100,046,783A>C variant. This change has been identified in a single family with two affected individuals, a mother and her son; although the mother had typical findings of NCMD, the child had broader retinal involvement and has been documented to have a related developmental disorder, progressive bifocal chorioretinal atrophy (PBCRA). 2 Notably, an adjacent variant, chr6:100,046,804T>C (orange line in the variant row of the Figure), has been reported to cause PBCRA in six affected individuals from two families. 2 The fact that the candidate enhancer encompassing these two PBCRA-implicated variants appears to have a role in both macular and retinal tissue may explain why individuals carrying these changes can develop a phenotype that is more severe than classical NCMD and is associated with extramacular involvement.

DISCUSSION
In this study, we report clinical and genetic findings from six patients with NCMD. We highlight the usefulness of widefield retinal imaging in individuals suspected to have NCMD (Fig. 3) and discuss the need for monitoring for choroidal neovascularization, particularly in young affected children. Furthermore, we perform computational analysis of NCMDassociated changes, with the results further supporting the role of PRDM13 dysregulation in the pathogenesis of the condition.
Phenotypic variability is incompletely understood, but common in NCMD. 1,3 It is therefore not surprising that significant differences in clinical presentation were observed among the participants of this study. It is worth highlighting, however, that the three mildest cases were asymptomatic and were initially incorrectly diagnosed in adulthood as having a form of early onset macular drusen; OCT imaging revealed that these macular changes were unlike typical drusen (Fig. 2) and genetic testing highlighted the congenital nature of these lesions. It is noteworthy that histopathologic examination of an enucleated eye from a 72-year-old patient with a clinical diagnosis of NCMD revealed sub-RPE deposits. 43 However, OCT findings from this and other studies 9 suggest that at least a subset of these lesions may be anterior to the RPE. The most severely affected participant in this study was a 6-year-old male patient who had coloboma-like excavation and subretinal fibrosis in both maculae. Notably, he experienced moderate to severe visual loss owing to the formation of choroidal neovascularization. This is a rare but sight-threatening complication of NCMD that can occur in both children and adults. 1,5,[44][45][46] A previous report has shown that intravitreal bevacizumab injections can improve vision and decrease intraretinal fluid. However, multiple injections (in a treat-and-extend protocol) may be required. 45 We highlight an under-recognized fundoscopic finding of NCMD: multiple drusen-like spots in the peripheral retina. These lesions were noted in all study participants and were easily detected on widefield retinal imaging (Fig. 3). Although this feature is not pathognomonic, it prompted targeted genetic testing in one of the probands. Similar retinal abnormalities have been previously described in a number of affected families, including in the original NCMD kindred. 5,6,11,44,47,48 These peripheral lesions should, therefore, be sought after in all individuals with a clinical presentation suggestive of NCMD and their presence should provide additional justification for requesting focused genetic screening. Further retinal imaging, including widefield OCT, is expected to provide important insights into the nature of this common but frequently overlooked feature of NCMD.
Although a number of noncoding genetic variants have been associated with NCMD, our understanding of the molecular pathology of this condition remains incomplete. The recent emergence of comprehensive functional genomic datasets from adult and fetal human tissues 20,21,26 has enabled the in-depth analysis of noncoding changes like the ones implicated in this disorder. We found that all NCMDassociated variants fall within enhancer elements that appear to be active during development and to be linked to the retinal transcription factor PRDM13. A number of observations relating to our in silico analysis are worthy of further discussion. First, the candidate enhancer that encompasses chr6:100,040,987G>C, the variant carried by the six study participants, was absent when retina-derived epigenomic data were used and was only highlighted when a dataset from macular tissue was used (Fig. 4). Second, there were stark differences in the computational predictions of the ABC algorithm depending on the type of Hi-C data used as input (averaged/non-tissue-specific vs. embryonic tissuespecific profiles). This finding is notable because the developers of the ABC algorithm concluded that a Hi-C profile generated by averaging over several tissue types performed equally well to tissue-specific data. However, our findings indicate a potential pitfall in using averaged Hi-C data for genes that are most highly expressed during development.
The human retina emerges in three main stages. The early retina is characterized by retinal progenitor proliferation and RPE emergence (5-7 postconception weeks); this period is followed by ganglion cell production and initiation of the programs that underlie the development of horizontal cells, amacrine cells, and cone photoreceptors (7-10 postconception weeks). Subsequently, cone, amacrine, rod, bipolar, and Muller glia cells sequentially emerge (12-18 postconception weeks). 49,50 Interestingly, the morphologic differentiation of the fovea is completed earlier than other regions for all cell types. 49 Our gene expression analyses of human tissues revealed that PRDM13 is expressed predominantly in the retinal progenitor and the amacrine cell populations. Amacrine cells are the most diverse class of retinal neurons and are often subdivided based on the expression of inhibitory γ -aminobutyric (GABA) or glycine. Studies in animal models have shown that PRDM13 is a key determinant of amacrine cell fate and promotes the generation of amacrine cell subtypes (with a bias toward a glycinergic phenotype). Given that duplications of the PRDM13 region are an established cause of NCMD, it has been proposed that over-expression of this gene during development is the main disease mechanism. 16 This is supported by findings in Drosophila, Xenopus, and murine retinae, although none of these animal models has a macula. 51,52 How impaired amacrine cell specification leads to macular abnormalities remains unclear. It is noteworthy though that the inner retinal layers (including the amacrine cell bodies) seemed to be normal on OCT imaging (Fig. 2). Previous studies have however reported cases with subtle foveal hypoplasia 3 or electrophysiologic findings, 16 suggesting amacrine cell abnormalities. These reports are, however, sporadic and the in-depth phenotyping of more affected individuals will provide further insights.
In conclusion, we have used human transcriptomic and epigenomic datasets to study the disease mechanism of NCMD. We highlight the value of computational approaches for the evaluation of candidate noncoding variants and discuss the importance of taking spatiotemporal context into account in these analyses. Furthermore, we report a common peripheral retinal finding challenging the notion that NCMD is a disorder strictly confined to the macula.